Garnet Equity Capital Holdings, Inc. Krystal Biotech, Inc. Transaction History

Garnet Equity Capital Holdings, Inc.

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2021 Apr 26, 2021	SELL	$59.42 - $85.46 $1.19 Million - $1.71 Million	-20,000 Closed	0 $0
Q4 2020 Feb 08, 2021	SELL	$40.64 - $61.38 $812,800 - $1.23 Million	-20,000 Reduced 50.0%	20,000 $1.2 Million
Q2 2020 Aug 04, 2020	BUY	$37.03 - $60.0 $1.48 Million - $2.4 Million	40,000 New	40,000 $1.66 Million
Q1 2020 May 05, 2020	SELL	$35.02 - $65.64 $420,240 - $787,680	-12,000 Closed	0 $0
Q4 2019 Jan 14, 2020	SELL	$33.17 - $65.23 $530,720 - $1.04 Million	-16,000 Reduced 57.14%	12,000 $665,000
Q3 2019 Oct 17, 2019	SELL	$34.72 - $51.3 $590,240 - $872,100	-17,000 Reduced 37.78%	28,000 $972,000
Q2 2019 Jul 15, 2019	BUY	$27.2 - $41.2 $1.22 Million - $1.85 Million	45,000 New	45,000 $1.81 Million

302

24.5M

444K

325K

Ticker KRYS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 25,664,300
Market Cap $3.93B
Description
Krystal Biotech, Inc., a clinical stage biotechnology company, engages in the field of redosable gene therapy to treat serious rare diseases in the United States. Its lead product candidate is beremagene geperpavec (B-VEC), which is in Phase III clinical study to treat dystrophic epidermolysis bullosa. The company is also involved in developing ...

Get notified when there are updates to the investment portfolio of Garnet Equity Capital Holdings, Inc., based on Form 13F filings with the SEC.

Stay updated on Garnet Equity Capital Holdings, Inc. with notifications on news.